APP
DYN icon

Alpha Paradigm Partners’s Dyne Therapeutics DYN Stock Holding History

Alpha Paradigm Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,630
Closed -$440K – 514
2022
Q3 		$440K Buy
+34,630
New +$397K 0.19% 181

Other funds holding DYN

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alpha Paradigm Partners's DYN Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of Dyne Therapeutics (DYN) in Q4 2022, closing a stake of 34,630 shares — an estimated $440K sold.

Alpha Paradigm Partners first reported a position in DYN in Q3 2022 and held it in 1 quarter. The position peaked at $440K in Q3 2022. 113 funds tracked by Wall St. Rank hold DYN as of Q4 2022.

  • Alpha Paradigm Partners reported no remaining Dyne Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Alpha Paradigm Partners sold 34,630 Dyne Therapeutics shares in Q4 2022, an estimated $440K.
  • Alpha Paradigm Partners first reported a position in Dyne Therapeutics in Q3 2022 and held it in 1 quarter.
  • Alpha Paradigm Partners's Dyne Therapeutics position peaked at $440K in Q3 2022.
  • 113 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.